Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds BTIG Maintains Buy on MaxCyte, Raises Price Target to $11

BTIG Maintains Buy on MaxCyte, Raises Price Target to $11

BTIG analyst Mark Massaro maintains MaxCyte (NASDAQ:MXCT) with a Buy and raises the price target from $10 to $11.

byBenzinga Newsdesk

August 15, 2022

1 minute read

BTIG analyst Mark Massaro maintains MaxCyte (NASDAQ:MXCT) with a Buy and raises the price target from $10 to $11.

Booz Allen Hamilton, Uber And 2 Other Stocks Insiders Are Selling

By Lisa Levin

July 20, 8:26 AM

The Nasdaq 100 closed slightly lower on Wednesday. Investors, meanwhile, focused on some notable insider trades.

ANF

Kevin O’Leary, On FTX, Says He’s Going To ‘Find Where My Money Went,’ Says He’s A ‘Pissed Off Cowboy’ -From Benzinga’s Future Of Crypto Event

By Benzinga Newsdesk

December 7, 10:19 AM

-From Benzinga's Future Of Crypto Event

BTC

Microchip Technology Sees Q2 EPS $1.60-$1.64 Vs $1.63 Est.; Revenue $2.22B-$2.312B Vs $2.28B Est.

By Benzinga Newsdesk

August 3, 4:28 PM

Second Quarter Fiscal Year 2024 Outlook:The following statements are based on current expectations. These statements are forward-looking, and actual results may differ materially.Microchip Consolidated Guidance Net

MCHP

What’s Going On With Health Insurance Firm UnitedHealth Stock Today?

By Vandana Singh

February 8, 12:44 PM

Explore UnitedHealth Group Inc stock insights! Discover recent market trends, CEO perspectives, and financial highlights.

CVS

BTIG Maintains Buy on MaxCyte, Raises Price Target to $11

Related Posts

Booz Allen Hamilton, Uber And 2 Other Stocks Insiders Are Selling

Kevin O’Leary, On FTX, Says He’s Going To ‘Find Where My Money Went,’ Says He’s A ‘Pissed Off Cowboy’ -From Benzinga’s Future Of Crypto Event

Microchip Technology Sees Q2 EPS $1.60-$1.64 Vs $1.63 Est.; Revenue $2.22B-$2.312B Vs $2.28B Est.

What’s Going On With Health Insurance Firm UnitedHealth Stock Today?